Study shows how pituitary macrophages impact hormone regulation

The FDA approved injectable Jubbonti and Wyost as the first interchangeable biosimilars to denosumab (Prolia, Xgeva), and for all the same indications, including the prevention

Rare neu­ro­log­i­cal dis­ease drug de­vel­op­er Har­mo­ny Bio­sciences ac­quired Epy­genix Ther­a­peu­tics and its pipeline of treat­ments for rare epilep­sy con­di­tions. Har­mo­ny paid $35 mil­lion up­front, and